Rheumatology

Health Canada changes follow U.S. findings of increased risk of death with febuxostat compared with allopurinol

Oral steroid use in patients with the inflammatory diseases polymyalgia rheumatica and/or giant cell arteritis significantly increased the risk of infection, and the risk increased with higher doses

Five-year study will examine real-world comparative efficacy and safety in rheumatologic conditions and inflammatory bowel disease.

Febuxostat (Uloric) increases risk of heart-related death and death from all causes compared with allopurinol

Canadian Rheumatology Association provides guidance to ensure empathetic care and harm reduction

'Drug holidays' cannot be safely taken in patients treated with denosumab